Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1345 of 5804
-
New implant could help sleep apnea patients ditch the CPAP mask
Disease control CompletedProspective, multicenter, open-label study designed to confirm device performance of Inspire system in Singapore.
Phase: NA • Sponsor: Inspire Medical Systems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a sleep pill boost antidepressants for tough depression?
Symptom relief Recruiting nowThe purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder w…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Can an app improve life for metastatic breast cancer patients?
Symptom relief Recruiting nowThe goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy. The…
Phase: NA • Sponsor: UNICANCER • Aim: Symptom relief
Last updated Jun 26, 2026 12:46 UTC
-
Shock therapy at home? new study hopes to sharpen focus in veterans with brain injury
Symptom relief Recruiting nowThe proposed study will evaluate a new approach to cognitive rehabilitation of mTBI using a brain stimulation technique called "Remotely Supervised Transcranial Direct Current Stimulation combined with Cognitive Training" (RS-tDCS+) which has shown promise for improving complex a…
Phase: NA • Sponsor: United States Naval Medical Center, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
New MRI dye aims to sharpen detection of dangerous prostate cancers
Diagnosis Recruiting nowThis phase 1b open label, dose-escalating investigation study is to evaluate the dose dependent initial efficacy of the use of MT218 injection for biomarker targeted MR molecular imaging (MRMI) of prostate cancer in patients scheduled for radical prostatectomy.
Phase: PHASE1, PHASE2 • Sponsor: Songqi Gao • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
New zap-and-heal catheter aims to fix irregular heartbeat without long-term drugs
Disease control Recruiting nowThe objective of this study is to demonstrate initial safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA or nano-PFA) 360 Catheter Endocardial Ablation System in treating subjects with atrial fibrillation.
Phase: NA • Sponsor: Pulse Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill AC-003 tested for severe transplant complication
Disease control Recruiting nowThe study was an open-label, single-arm, dose-escalation, Phase Ib, multi-center study to investigate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of AC-003 in patients with grade II-IV SR-aGVHD.
Phase: PHASE1 • Sponsor: Accro Bioscience (Suzhou) Limited • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New heart mapping tech could improve AFib treatment
Disease control Recruiting nowThis is a global, multi-site, prospective, feasibility study.
Phase: NA • Sponsor: CoreMap Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for FSHD: Long-Term drug safety trial underway
Disease control OngoingA Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase: PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug BL-M17D1 enters first human trial for Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in locally advanced or metastatic HER2 positive/lower expre…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:16 UTC
-
New CAR-T therapy targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of FAST CAR…
Phase: PHASE1 • Sponsor: Weijia Fang, MD • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cancer drug MRG006A enters human trials for advanced tumors
Disease control Recruiting nowThe objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.
Phase: PHASE1, PHASE2 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New study tracks how SMA kids change on modern treatments
Knowledge-focused Recruiting nowWith the advent of new treatments for ASI, new phenotypes are emerging. The investigators propose to describe these new phenotypes by prospectively following children with ASI of all types treated with TRS and aged under 16 for 2 years. The investigators also propose to evaluate…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Second chance: blood test guides retreatment for tough colorectal cancer
Disease control OngoingThe aim of this study is to evaluate the activity, in terms of best response according to RECIST criteria 1.1 as assessed by the local investigator, of the ctDNA-guided retreatment with encorafenib plus cetuximab in BRAFV600E mutated mCRC patients experiencing benefit from previo…
Phase: PHASE2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for advanced cancers? first human trial launches
Disease control Recruiting nowThis is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Prison vaccine push aims to save lives behind bars
Prevention Recruiting nowThe goal of this study is to reduce morbidity and mortality from COVID-19 amongst people who are detained in and work in correctional facilities. The overall objective is to identify feasible and effective interventions to improve vaccine uptake in correctional facilities and stu…
Phase: NA • Sponsor: Yale University • Aim: Prevention
Last updated Jun 27, 2026 07:59 UTC
-
Experimental virus therapy takes on Drug-Resistant lung cancer
Disease control OngoingThis is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.
Phase: PHASE1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Zapping cancer spots: new radiation strategy may extend current Drug's power
Disease control Recruiting nowThis phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first started to other places in the body (metastatic) and has limited disease progression (…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New blood clot pill could replace daily shots for joint replacement patients
Prevention CompletedThis clinical study aims to evaluate the efficacy and safety of the anticoagulant Dimolegin® compared to low molecular weight heparin (Clexane®) for the prevention of venous thromboembolic events (VTE) in patients undergoing major joint (hip or knee) replacement surgery. The stud…
Phase: PHASE3 • Sponsor: Avexima Diol LLC • Aim: Prevention
Last updated Jun 27, 2026 08:11 UTC